Therapy News and Research

RSS

Dietary amino acids improve sleep disturbances caused by brain injuries in animals

Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.

12 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

A recent Mayo Clinic study found that people with chronic obstructive pulmonary disease (COPD) are about twice as likely to develop mild cognitive impairment (MCI) -- and chances are that it will include memory loss. The study was recently published in Mayo Clinic Proceedings.

12 Dec 2013

New web-based tool developed to aid health professionals determine right treatment for injured workers

University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.

12 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

A team of researchers from Brigham and Women's Hospital, Boston Medical Center and Massachusetts General Hospital has been awarded $25 million by the National Institutes of Health to conduct a four-year, randomized clinical trial-the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia.

11 Dec 2013

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

Absorption Pharmaceuticals LLC in collaboration with Kaiser Permanente announced today the initiation of a clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation. This Phase III, double blind, placebo-controlled, randomized study will measure the intravaginal ejaculatory latency time for subjects aged 18 and older.

11 Dec 2013

FDA advisory committee votes in favor of WATCHMAN Left Atrial Appendage Closure device

The U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the WATCHMAN Left Atrial Appendage Closure device outweigh the risks.

11 Dec 2013

Low sodium levels linked to poor targeted therapy outcomes in RCC

Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.

11 Dec 2013

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows.

11 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

Queen's University heads key European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a €6 million European study to find new treatments for bowel cancer.

11 Dec 2013

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

...

11 Dec 2013

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

New family of drugs may help combat childhood tumor

St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Therapy News and Research

Dietary amino acids improve sleep disturbances caused by brain injuries in animals

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

New web-based tool developed to aid health professionals determine right treatment for injured workers

New drug combination therapy effective for patients with HER2-positive breast cancer

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

FDA advisory committee votes in favor of WATCHMAN Left Atrial Appendage Closure device

Low sodium levels linked to poor targeted therapy outcomes in RCC

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Crealta to acquire all assets of Savient Pharmaceuticals

Queen's University heads key European study to find new treatments for bowel cancer

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Detectable blood viral load increases prevalence of heart disease

New family of drugs may help combat childhood tumor

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News